Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
Li V, McKay FC, Tscharke DC, Smith C, Khanna R, Lechner-Scott J, Rawlinson WD, Lloyd AR, Taylor BV, Morahan JM, Steinman L, Giovannoni G, Bar-Or A, Levy M, Drosu N, Potter A, Caswell N, Smith L, Brady EC, Frost B, Hodgkinson S, Hardy TA, Broadley SA; Australian Anti-EBV Drugs for MS Working Group.
Li V, et al. Among authors: drosu n.
CNS Drugs. 2025 Jan 10. doi: 10.1007/s40263-024-01153-5. Online ahead of print.
CNS Drugs. 2025.
PMID: 39792343